Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. (TARS) stock has experienced several notable events in the past six months. As of April 2, 2026, the share price was $70.12, marking a 47.65% increase from April 7, 2025. Over the past year, the stock has traded between a 52-week low of $38.51 and a 52-week high of $85.25. Key events include dosing the first participant in its Phase 2 clinical trial for TP-05, the approval of TP-03 in China triggering a $15 million milestone payment, insider selling by key executives, reporting strong net product sales of XDEMVY reaching $451.4 million for the full year 2025 with full-year 2026 net product sales guidance between $670 million and $700 million, reporting approximately $119 million in XDEMVY net sales for the third-quarter 2025, and participation in investor conferences.

Tarsus Pharmaceuticals, Inc. experiences demand seasonality for its products. Management has cited first quarter seasonality, deductible resets, and weather disruptions as factors impacting near-term sales trends for XDEMVY.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for eye care, dermatology, and infectious disease prevention. The company's flagship product, XDEMVY, is the first and only FDA-approved therapeutic for Demodex blepharitis. Tarsus is also developing TP-04 for ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, California, and sells its products in the United States. The company is exploring international expansion, with potential approvals in Europe, Japan, and Greater China. TP-03 was approved in China for Demodex blepharitis in March 2026, and a preservative-free formulation of TP-03 is on track for potential approval in Europe by 2027.

Tarsus Pharmaceuticals has a positive brand reputation, particularly with XDEMVY. The FDA approval of XDEMVY in 2023 was a significant milestone, and it has been recognized as one of the best-selling prescription eye drops. The company has achieved broad coverage for XDEMVY across commercial, Medicare, and Medicaid plans, and has seen an expanding patient funnel. Over 20,000 eye care professionals have written multiple prescriptions for XDEMVY, reflecting its integration into clinical practice. There have been no specific events reported in the past year that have negatively affected Tarsus Pharmaceuticals, Inc.'s overall brand reputation.

Tarsus Pharmaceuticals, Inc. is predominantly owned by institutional investors, who collectively hold between 73.21% and 85.27% of the shares. Major institutional shareholders include BlackRock, Inc., RTW Investments, LP, Deep Track Capital, LP, Paradigm Biocapital Advisors LP, Vanguard Group Inc, Jennison Associates Llc, Morgan Stanley, Janus Henderson Group Plc, Tang Capital Management Llc, and Driehaus Capital Management Llc. Individual insiders hold approximately 3.32% of the company's shares.